EA201691634A1 - Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l - Google Patents
Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40lInfo
- Publication number
- EA201691634A1 EA201691634A1 EA201691634A EA201691634A EA201691634A1 EA 201691634 A1 EA201691634 A1 EA 201691634A1 EA 201691634 A EA201691634 A EA 201691634A EA 201691634 A EA201691634 A EA 201691634A EA 201691634 A1 EA201691634 A1 EA 201691634A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cd40l
- methods
- directed against
- transclantat
- release
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108010029697 CD40 Ligand Proteins 0.000 title abstract 2
- 102100032937 CD40 ligand Human genes 0.000 title abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 229960005347 belatacept Drugs 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955588P | 2014-03-19 | 2014-03-19 | |
| PCT/US2015/021551 WO2015143209A1 (en) | 2014-03-19 | 2015-03-19 | Methods of treating transplant rejection using a domain antibody directed against cd40l |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201691634A1 true EA201691634A1 (ru) | 2016-11-30 |
Family
ID=53055087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691634A EA201691634A1 (ru) | 2014-03-19 | 2015-03-19 | Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l |
Country Status (13)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102159590A (zh) | 2008-07-18 | 2011-08-17 | 百时美施贵宝公司 | Cd28结合为单价的组合物及使用方法 |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| AU2015325015A1 (en) | 2014-09-30 | 2017-05-18 | Bristol-Myers Squibb Company | Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28 |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| JP7256011B2 (ja) * | 2015-11-27 | 2023-04-11 | アブリンクス エン．ヴェー． | Ｃｄ４０ｌを阻害するポリペプチド |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| CN110662768B (zh) * | 2017-05-24 | 2024-01-30 | Als治疗发展学会 | 治疗性抗cd40配体抗体 |
| CN114423785B (zh) * | 2019-07-01 | 2025-04-22 | 通尼克斯制药有限公司 | 抗-cd154抗体及其用途 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| WO2005044294A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Method of therapy for cancers expressing the cd40 antigen |
| CN101198347A (zh) | 2005-04-06 | 2008-06-11 | 布里斯托尔-迈尔斯斯奎布公司 | 使用可溶性ctla4突变型分子治疗与移植物移植有关的免疫病症的方法 |
| PT1962886E (pt) | 2005-12-20 | 2014-01-07 | Bristol Myers Squibb Co | Formulações de proteína estáveis |
| CN102159590A (zh) | 2008-07-18 | 2011-08-17 | 百时美施贵宝公司 | Cd28结合为单价的组合物及使用方法 |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
-
2015
- 2015-03-19 MX MX2016011102A patent/MX2016011102A/es unknown
- 2015-03-19 KR KR1020167028617A patent/KR20160124912A/ko not_active Ceased
- 2015-03-19 EA EA201691634A patent/EA201691634A1/ru unknown
- 2015-03-19 US US15/122,455 patent/US20170051059A1/en not_active Abandoned
- 2015-03-19 CN CN201580014085.1A patent/CN106132429A/zh active Pending
- 2015-03-19 BR BR112016018813A patent/BR112016018813A2/pt not_active Application Discontinuation
- 2015-03-19 WO PCT/US2015/021551 patent/WO2015143209A1/en not_active Ceased
- 2015-03-19 SG SG11201606521VA patent/SG11201606521VA/en unknown
- 2015-03-19 JP JP2016558023A patent/JP2017509649A/ja not_active Withdrawn
- 2015-03-19 EP EP15721055.0A patent/EP3119809A1/en not_active Withdrawn
- 2015-03-19 CA CA2943177A patent/CA2943177A1/en not_active Abandoned
- 2015-03-19 AU AU2015231180A patent/AU2015231180B2/en not_active Ceased
-
2016
- 2016-08-01 IL IL247048A patent/IL247048A0/en unknown
-
2020
- 2020-01-31 US US16/779,059 patent/US20200231676A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015231180A1 (en) | 2016-08-11 |
| AU2015231180B2 (en) | 2017-06-15 |
| US20200231676A1 (en) | 2020-07-23 |
| IL247048A0 (en) | 2016-09-29 |
| US20170051059A1 (en) | 2017-02-23 |
| CA2943177A1 (en) | 2015-09-24 |
| MX2016011102A (es) | 2017-01-26 |
| KR20160124912A (ko) | 2016-10-28 |
| BR112016018813A2 (pt) | 2017-10-10 |
| EP3119809A1 (en) | 2017-01-25 |
| WO2015143209A1 (en) | 2015-09-24 |
| JP2017509649A (ja) | 2017-04-06 |
| CN106132429A (zh) | 2016-11-16 |
| SG11201606521VA (en) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691634A1 (ru) | Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l | |
| EA201590388A1 (ru) | Способы лечения таупатии | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| EA201892193A1 (ru) | Химерные рецепторы к flt3 и способы их применения | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| NZ737796A (en) | Anti-tau antibodies and methods of use | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| EA201891992A1 (ru) | Химерные рецепторы и способы их применения | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| EA201790439A1 (ru) | Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами | |
| EP3964527A3 (en) | Combination therapy for cancer | |
| EA201692039A1 (ru) | ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| EA201501063A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA201790248A1 (ru) | Композиции носитель-антитело и способы их получения и применения | |
| EA201791270A1 (ru) | Модифицированные april-связывающие антитела | |
| PH12016501366A1 (en) | Novel anti-baff antibodies |